BIOMAT Database Logo BIOMAT Database Logo

[Use of curantyl in nephritis]. 1988

V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Use of curantyl in diffuse glomerulonephritis].
May 1977, Klinicheskaia meditsina,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Quantitative spectrophotometric determination of curantyl].
January 1977, Farmatsevtychnyi zhurnal,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Use of curantyl in combination with potassium-containing preparations in chronic ischemic heart disease].
February 1976, Klinicheskaia meditsina,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Use of calciparin, curantyl and polopirin S in the treatment of retinal vein thrombosis].
March 1984, Klinika oczna,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Clinical and hemostatic evaluation of curantyl in hypertensives].
October 1991, Kardiologiia,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Influencing thrombocyte function with dipyridamol (Curantyl)].
November 1972, Das Deutsche Gesundheitswesen,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Treatment of angina pectoris with dipyridamol (Curantyl, Germed)].
July 1978, Zeitschrift fur arztliche Fortbildung,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[The use of dipyridamole (curantyl) in combination with alpha-lipoic acid in the treatment of diabetic neuropathy with retinopathy].
January 2008, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
Use of cyclosporin in lupus nephritis.
January 1995, Contributions to nephrology,
V A Rogov, and I E Tareeva, and I M Kutyrina, and A A Nekrasova, and V A Tatsievskiĭ
[Use of levamisole in experimental nephritis].
January 1982, Farmakologiia i toksikologiia,
Copied contents to your clipboard!